Who are Rosuvastatin-ranitidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosuvastatin-ranitidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rosuvastatin-ranitidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rosuvastatin-ranitidine (Rosuvastatin-ranitidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist. Area: Cardiovascular.

marketed Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rosuvastatin-ranitidine (Rosuvastatin-ranitidine) — Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. This is a fixed-dose combination of rosuvastatin (a statin that lowers cholesterol) and ranitidine (an H2-receptor antagonist that reduces stomach acid).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rosuvastatin-ranitidine TARGET	Rosuvastatin-ranitidine	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist	HMG-CoA reductase (rosuvastatin component); Histamine H2 receptor (ranitidine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination: HMG-CoA reductase inhibitor + H2-receptor antagonist class)

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rosuvastatin-ranitidine — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-ranitidine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing